Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated...

Area of Science:

• Oncology
• Prostate Cancer Research
• Clinical Prognostics

Background:

• Limited real-world data exists for prognostic models in metastatic castration-resistant prostate cancer (mCRPC) patients treated with androgen-receptor signaling inhibitors (ARSI).
• Existing models primarily focus on chemotherapy, necessitating new tools for ARSI-treated populations.

Purpose of the Study:

• To develop and validate a prognostic model for overall survival (OS) in mCRPC patients receiving first-line ARSI.
• To identify key clinical and laboratory variables predictive of OS in this patient group.

Main Methods:

• A consecutive series of 565 mCRPC patients receiving first-line ARSI formed the development set.
• An external validation set of 180 patients was used to confirm the model's performance.
• Sixteen clinical and baseline laboratory variables were assessed; multivariate analysis identified significant predictors for OS.

Main Results:

• The final model incorporated 7 variables: age, PSA doubling time, hemoglobin, PSA levels, time to castration resistance, ECOG PS, and bone metastasis count.
• Median OS varied significantly across risk groups: 13.4 months (poor), 25.7 months (intermediate), and 46.4 months (good).
• The model demonstrated good prognostic ability with c-indexes of 0.68 (development) and 0.75 (validation).

Conclusions:

• A novel prognostic model effectively predicts OS in mCRPC patients receiving first-line ARSI.
• The model utilizes easily accessible clinical and laboratory data, facilitating practical application in routine clinical practice.
• This tool aids in risk stratification and personalized treatment planning for mCRPC patients on ARSI therapy.